Table of contents


Research Highlights

Gastrointestinal cancer: Regorafenib, the CORRECT way forward or just another GRIDlock? | PDF (130 KB)

p1 | doi:10.1038/nrgastro.2012.242

NAFLD: Getting to the heart of NAFLD | PDF (110 KB)

p2 | doi:10.1038/nrgastro.2012.243

Microbiota: Gut microbes might promote intestinal angiogenesis | PDF (198 KB)

p3 | doi:10.1038/nrgastro.2012.227

Therapy: Potential of siRNA-based therapies for pancreatic fibrosis | PDF (258 KB)

p3 | doi:10.1038/nrgastro.2012.237

Diagnosis: New noninvasive test to diagnose NASH by analysing exhaled breath | PDF (46 KB)

p4 | doi:10.1038/nrgastro.2012.226

Hepatitis: Complexities of HBV quasispecies | PDF (44 KB)

p4 | doi:10.1038/nrgastro.2012.238

Genetics: Variants in SBF2 gene associated with survival in pancreatic adenocarcinoma | PDF (47 KB)

p4 | doi:10.1038/nrgastro.2012.244

In brief

Helicobacter pylori: New endoscopic findings could confirm success of Helicobacter pylori eradication | PDF (50 KB)

p2 | doi:10.1038/nrgastro.2012.228

Pancreatitis: Genetic advances in alcohol-associated pancreatitis | PDF (50 KB)

p2 | doi:10.1038/nrgastro.2012.231

Top

News and Views

IBD: Postoperative VTE prophylaxis in IBD

Geoffrey C. Nguyen

p5 | doi:10.1038/nrgastro.2012.233

The risk of venous thromboembolism (VTE) is known to be increased in patients with IBD. However, no specific consensus statements exist regarding the prevention of postoperative VTE in patients with this disease. The results of a large retrospective cohort study quantifying the risk of postoperative VTE in patients with IBD are discussed.

Helicobacter pylori: Tailored therapy with novel sequential quadruple therapies

David Y. Graham & Javier P. Gisbert

p6 | doi:10.1038/nrgastro.2012.232

Treatment success for Helicobacter pylori, a major human pathogen, with popular drug regimens has generally declined to unacceptably low levels. As part of the worldwide effort to identify novel drug regimens that will reliably achieve high levels of success, Tay, Marshall and colleagues report their results with novel multidrug-tailored therapies.

Ulcerative colitis: Steroid-refractory ulcerative colitis—ciclosporin or infliximab?

Manreet Kaur & Stephen R. Targan

p8 | doi:10.1038/nrgastro.2012.235

Ciclosporin and infliximab are used as rescue therapies for the treatment of severe steroid-refractory ulcerative colitis. Now, an open-label, head-to-head randomized controlled trial has demonstrated that these drugs are well-tolerated and have equivalent efficacy in inducing short-term clinical response, mucosal healing and decreasing colectomy rates at 3 months.

Infection: Treating recurrent C. difficile infection—the challenge continues

Christina M. Surawicz

p10 | doi:10.1038/nrgastro.2012.240

Treatment of recurrent Clostridium difficile infection is challenging. New research now replicates human disease in a mouse model, shedding light on why antibiotics often fail to prevent further recurrences and demonstrating that targeted manipulation of the gut microbiota could be a feasible treatment option.

Top

Reviews

New treatments for IBS

Magnus Halland & Nicholas J. Talley

p13 | doi:10.1038/nrgastro.2012.207

IBS is a common disorder that can have an enormous negative effect on patients and society as a whole; however, many patients do not achieve adequate symptom relief with the currently available therapies. In this Review, Magnus Halland and Nicholas Talley discuss the latest treatments for IBS, including novel nonpharmacological and pharmacological approaches.

Diagnosis of hepatitis E

Rakesh Aggarwal

p24 | doi:10.1038/nrgastro.2012.187

Hepatitis E is common in developing countries, and occasional cases of this disease have been identified in developed countries. The currently available diagnostic tests have undergone limited testing and often yield discordant results. In this article, Rakesh Aggarwal reviews the information on diagnosis of hepatitis E, including past and current diagnostic tests.

See also: Correspondence by Linghua & Xinguang | Correspondence by Aggarwal

Medical therapies for hepatocellular carcinoma: a critical view of the evidence

Augusto Villanueva, Virginia Hernandez-Gea & Josep M. Llovet

p34 | doi:10.1038/nrgastro.2012.199

As the burden of hepatocellular carcinoma (HCC) continues to increase, attention turns to the appropriate management of the disease. In this Review, the authors discuss and critique the currently available medical interventions for the treatment and management of HCC, as well as introduce future developments in the field.

Development and developmental disorders of the enteric nervous system

Florian Obermayr, Ryo Hotta, Hideki Enomoto & Heather M. Young

p43 | doi:10.1038/nrgastro.2012.234

The enteric nervous system (ENS) arises from neural crest-derived cells. Here, Heather Young and colleagues provide an overview of the progress made in the past five years in our understanding of ENS development and the potential involvement of defects in ENS development in paediatric motility disorders.

Top

Perspectives

Opinion

Refractory inflammatory bowel disease—could it be an irritable bowel?

Jie Meng, Anurag Agrawal & Peter J. Whorwell

p58 | doi:10.1038/nrgastro.2012.173

Patients with IBD who are reportedly in remission, but continue to have symptoms of abdominal discomfort and bowel dysfunction, could have IBS in addition to IBD. This Perspectives article examines the relationship between IBS and IBD, and discusses how to diagnose and treat IBS in patients with co-existing IBD.

Extra navigation

Subscribe

Subscribe to Nature Reviews Gastroenterology and Hepatology

Advertisement